DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Apixaban

Apixaban

  • Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort O

    Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort O

  • Clinical Protocol

    Clinical Protocol

  • STUDY PROTOCOL Study Information Title Apixaban Drug

    STUDY PROTOCOL Study Information Title Apixaban Drug

  • Standard-Dose Apixaban After Very Low-Dose Thrombolysis for Acute Intermediate-High Risk Acute Pulmonary Embolism

    Standard-Dose Apixaban After Very Low-Dose Thrombolysis for Acute Intermediate-High Risk Acute Pulmonary Embolism

  • New Age of Anticoagulants

    New Age of Anticoagulants

  • Edoxaban Switch Programme - Frequently Asked Questions

    Edoxaban Switch Programme - Frequently Asked Questions

  • SIGN 129 • Antithrombotics: Indications and Management

    SIGN 129 • Antithrombotics: Indications and Management

  • Emergency Management of Patients on Direct Oral Anticoagulants (Doacs)

    Emergency Management of Patients on Direct Oral Anticoagulants (Doacs)

  • Apixaban (Eliquis®) What You Need to Know

    Apixaban (Eliquis®) What You Need to Know

  • Presentazione Standard Di Powerpoint

    Presentazione Standard Di Powerpoint

  • Anticoagulation Guidelines for COVID 19 Patients Riverside Health System

    Anticoagulation Guidelines for COVID 19 Patients Riverside Health System

  • Therapeutic Class Overview Oral Anticoagulants

    Therapeutic Class Overview Oral Anticoagulants

  • Elective Surgery and Invasive Procedures in Patients Taking

    Elective Surgery and Invasive Procedures in Patients Taking

  • The Pharmacodynamic Effect of ELIQUIS Can Be Expected to Persist for at Least 24 Hours After the Last Dose, Ie, for About Two Drug Half Lives

    The Pharmacodynamic Effect of ELIQUIS Can Be Expected to Persist for at Least 24 Hours After the Last Dose, Ie, for About Two Drug Half Lives

  • Apixaban and Rosuvasłłtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease

    Apixaban and Rosuvasłłtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease

  • Low Dosis of Alteplase, for Ischemic Stroke After Enchanted and Its Determinants, a Single Center Experience

    Low Dosis of Alteplase, for Ischemic Stroke After Enchanted and Its Determinants, a Single Center Experience

  • Study Protocol

    Study Protocol

  • Combining Antiplatelets and Anticoagulants Example

    Combining Antiplatelets and Anticoagulants Example

Top View
  • NON-INTERVENTIONAL (NI) STUDY PROTOCOL Post
  • COVID-19 Vaccine Astrazeneca (Other Viral Vaccines) EPITT No:19683
  • Inclusions and Exclusions for IV
  • Eliquis (Apixaban)
  • Eliquis 2.5 Mg Film-Coated Tablets
  • Managing New Oral Anticoagulants in the Perioperative and Intensive
  • Treatment with Apixaban | Eliquis |
  • ELIQUIS Product Monograph
  • Switching from Warfarin to ELIQUIS® (Apixaban) Patient Information Booklet
  • Guidance on Safe Switching of Warfarin to DOAC
  • Prescriptions of Direct Oral Anticoagulants in Patients Admitted
  • Quantification of Apixaban in Human Plasma Using Ultra Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry
  • Rivaroxaban and Apixaban for DVTVTE Prophylaxis
  • Apixaban) Tablets
  • Anti-Platelet and Anti-Coagulant Prescriptions and Breast Cancer Recurrence: a Danish Nationwide Prospective Cohort Study
  • Comparison of New Anticoagulants to Warfarin and Low-Molecular-Weight Heparin
  • ELIQUIS Safely and Effectively
  • Which Direct Oral Anticoagulant (DOAC) Is Best for My Patient?


© 2024 Docslib.org    Feedback